News

With an estimated 1.37 billion inhabitants, India will likely surpass China in five years as the world’s most populous country. That also means it will have more rare-disease patients than any nation. It already has more than twice as many as the 28-member European Union. Harsha K. Rajasimha, a genomics…

Alexion Pharmaceuticals‘ Soliris (eculizumab) significantly reduces fatigue perceived by patients with generalized myasthenia gravis, a study finds. The study, “Eculizumab improves fatigue in refractory generalized myasthenia gravis,” was published in Quality of Life Research. Myasthenia gravis (MG) is an autoimmune disease caused…

Soliris (eculizumab) may be the most effective and well-tolerated immunotherapy for patients with myasthenia gravis (MG), according to an analysis of multiple studies. The research, “Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta‐analysis,” was published in the journal CNS Neuroscience…